Pharma Firms May Be Due A Refund Under UK Voluntary Price Scheme
Companies that chose to stay in the UK’s voluntary pricing scheme (VPAS) could be entitled to a refund on their rebate payments, while those that have left may end up paying more.
You may also be interested in...
New report on UK medicines manufacturing advises the government to improve voluntary scheme on medicine pricing to drive growth.
The UK government is standing its ground on this year’s hike in the statutory pricing scheme rebate, despite industry worries about the impact on companies’ investment decisions.
The pharmaceutical industry says financial uncertainties are a key reason why the English Innovative Medicines Fund (IMF) – offering the potential for time-limited funding for promising non-cancer treatments where benefits are uncertain at launch - has still not been used a year after it was put in place. Industry wants the National Health Service to share the financial risk of taking part in the fund.